Format

Send to

Choose Destination
Curr Opin Pharmacol. 2012 Aug;12(4):510-8. doi: 10.1016/j.coph.2012.06.002. Epub 2012 Jun 28.

New developments in Toll-like receptor targeted therapeutics.

Author information

1
Trinity Biomedical Sciences Institute, School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland.

Abstract

Toll-like receptors (TLRs) play a crucial role in host defence and inflammation. Given that a significant amount of evidence implicates TLRs in the pathogenesis of immune diseases and cancer, and their activation occurs early in the inflammatory cascade, they are attractive targets for novel therapeutic agents. Potential therapeutics include TLR-targeted antibodies, small molecules and nucleic acid based drugs. Agonists are being tested in vaccines against hepatitis C and influenza as well as in allergic rhinitis and certain cancers. Antagonists are being tested in ischemia/reperfusion injury, systemic lupus erythematosus and psoriasis. The prospect of targeting TLRs in multiple pathologies continues to hold much promise.

PMID:
22748800
DOI:
10.1016/j.coph.2012.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center